Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 1
2020 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators. Borghaei H, et al. Ann Oncol. 2024 Jan;35(1):66-76. doi: 10.1016/j.annonc.2023.10.004. Epub 2023 Oct 20. Ann Oncol. 2024. PMID: 37866811 Clinical Trial.
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer.
Puyalto A, Rodríguez-Remírez M, López I, Iribarren F, Simón JA, Ecay M, Collantes M, Vilalta-Lacarra A, Francisco-Cruz A, Solórzano JL, Sandiego S, Peñuelas I, Calvo A, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: sandiego s. Front Immunol. 2023 Sep 28;14:1272570. doi: 10.3389/fimmu.2023.1272570. eCollection 2023. Front Immunol. 2023. PMID: 37841258 Free PMC article.
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A, Rodríguez-Remírez M, López I, Macaya I, Guruceaga E, Olmedo M, Vilalta-Lacarra A, Welch C, Sandiego S, Vicent S, Valencia K, Calvo A, Pio R, Raez LE, Rolfo C, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: sandiego s. Mol Cancer. 2024 Apr 20;23(1):78. doi: 10.1186/s12943-024-01991-3. Mol Cancer. 2024. PMID: 38643157 Free PMC article.
Advanced systemic amyloidosis secondary to metastatic renal cell carcinoma.
Algarra MA, Fita MJJ, Sandiego S, Aguilar HA, Álvarez P, Quispe M, Salvador A, Egido A, Lavernia J, Machado I, Rubio-Briones J, Climent MÁ. Algarra MA, et al. Among authors: sandiego s. Ecancermedicalscience. 2020 Dec 15;14:1156. doi: 10.3332/ecancer.2020.1156. eCollection 2020. Ecancermedicalscience. 2020. PMID: 33574901 Free PMC article.
Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Herrero-Vicent C, Guerrero A, Gavilá J, Gozalbo F, Hernández A, Sandiego S, Algarra MA, Calatrava A, Guillem-Porta V, Ruiz-Simón A. Herrero-Vicent C, et al. Among authors: sandiego s. Ecancermedicalscience. 2017 Aug 15;11:759. doi: 10.3332/ecancer.2017.759. eCollection 2017. Ecancermedicalscience. 2017. PMID: 28900472 Free PMC article.
Erratum: Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year.
Herrero-Vicent C, Machado I, Illueca C, Avaria A, Salazar C, Hernandez A, Sandiego S, Lavernia J. Herrero-Vicent C, et al. Among authors: sandiego s. Ecancermedicalscience. 2016 Apr 27;10:637. doi: 10.3332/ecancer.2016.637. eCollection 2016. Ecancermedicalscience. 2016. PMID: 27350783 Free PMC article. No abstract available.